Biftu, Tesfaye published the artcileOmarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes, Safety of 2-(Methylsulfonyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole benzenesulfonate, the main research area is antidiabetic DPP4 inhibitor omarigliptin MK3102 preparation pharmacokinetics diabetes.
In our effort to discover DPP-4 inhibitors with added benefits over currently com. available DPP-4 inhibitors, MK-3102 (omarigliptin), was identified as a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an excellent pharmacokinetic profile amenable for once-weekly human dosing and selected as a clin. development candidate. This manuscript summarizes the mechanism of action, scientific rationale, medicinal chem., pharmacokinetic properties, and human efficacy data for omarigliptin, which is currently in phase 3 clin. development.
Journal of Medicinal Chemistry published new progress about Antidiabetic agents. 1280210-80-1 belongs to class pyrazoles-derivatives, name is 2-(Methylsulfonyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole benzenesulfonate, and the molecular formula is C12H15N3O5S2, Safety of 2-(Methylsulfonyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole benzenesulfonate.
Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics